Anastrozole

A prescription aromatase inhibitor approved for certain breast cancers in postmenopausal women. It is not FDA-approved as an adjunct to testosterone or non-medical anabolic-steroid use, though it circulates in that context to lower estradiol.

Anastrozole is a non-steroidal, reversible aromatase inhibitor: it binds the aromatase enzyme that converts androgens into estrogens and blocks it, so blood estradiol falls. In breast-cancer treatment that is the whole therapeutic point. In the non-medical context where it circulates alongside aromatising steroids, the same action is used to hold estradiol down — and because the binding is reversible and dose-dependent, the effect tracks how much is taken, which is exactly why overshoot is so easy. It does nothing about prolactin or progesterone, so it is the wrong tool for the side effects nandrolone and trenbolone actually cause.

Excellent evidence for its approved oncology indication. Evidence in men is limited and does not establish routine adjunctive use with testosterone, and over-suppressing estradiol does measurable harm.

• Oncology evidence is extensive and high quality — anastrozole is a first-line adjuvant breast-cancer drug with large randomised trials (the ATAC trial among them) behind that use.
• In men, small studies show it raises testosterone by reducing the estrogen feedback that suppresses the axis, and it has been studied in male hypogonadism and adolescent contexts — but with a consistent warning that lowering estradiol harms male bone density.
• For the physique use it actually gets — clamping estrogen during a steroid cycle — there is no controlled trial, and there could not ethically be one. The dosing is entirely community-derived, which is the origin of the overshoot problem.

An oral drug with a roughly 2-day half-life, so it accumulates over the first several days to a steady state rather than acting dose-by-dose — a big reason people who chase a high estradiol reading with extra doses end up crashed a few days later, well after the reading that alarmed them. The effect is reversible: stop it and aromatase activity returns, and estradiol climbs back.

Excessively suppressed estradiol is the big one: joint pain, reduced bone density over time, worsened lipids, low libido, low mood. Estrogen is not the enemy; men need it for bone, brain and vascular health. A randomised study in older men found reduced spine bone density, and bone-density loss with extended use is documented in the cancer literature.

• Men using it off a single immunoassay estradiol reading rather than a sensitive assay plus symptoms.
• Anyone with osteopenia, osteoporosis or a significant fracture history — it lowers the estradiol that protects bone.
• Anyone with an already poor lipid profile or cardiovascular disease.
• Anyone using it to counter a non-aromatising compound's side effects, where it does nothing useful.

• Aromatising steroids (testosterone, dianabol, oxymetholone) are the context it is used in; the pairing is a monitored balancing act, not a fixed add-on, and the compound entries for those carry the same caution.
• Tamoxifen reduces anastrozole blood levels (a documented pharmacokinetic interaction), which is one reason the two are not simply combined.
• Any other estrogen-lowering agent stacks toward a crash — arimistane, exemestane and letrozole all push the same direction.

Documented interactions with other things people research. A compound not listed here does not mean the combination is safe — only that no specific interaction is on file.

• Estradiol on a SENSITIVE (LC-MS/MS) assay — the standard immunoassay is unreliable in men and is behind a large share of unnecessary aromatase-inhibitor use.
• Symptoms, weighted at least as heavily as the number: joint pain, low libido, low mood and poor sleep are the signature of estrogen that has been pushed too low.
• Lipids — estrogen is cardioprotective in men, and suppressing it worsens the lipid picture a steroid cycle is already straining.
• Bone density on any prolonged use — the documented long-term cost of low estradiol in men.

Because the effect is reversible, stopping lets aromatase recover and estradiol return over days — usually uneventful. The harder scenario is stopping AFTER an overshoot: the low-estradiol symptoms (dead libido, aching joints, flat mood) persist until levels climb back, which takes days to a couple of weeks and is the toll people underestimate. Prolonged low estradiol also carries a bone-density cost that recovering estrogen does not instantly undo.

US: prescription-only (not scheduled). Products offered outside lawful prescription channels may be falsified or mislabeled.

• Anastrozole2006
• Anastrozole2012
• AnastrozoleExpert Opin Drug Saf · 2010
• AnastrozoleDrugs Today (Barc) · 2005
• Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trialLancet · 2016
• Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trialLancet · 2020
• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trialLancet Oncol · 2010
• Anastrozole-Associated Lichenoid EruptionAm J Ther · 2020
• Anastrozole (Arimidex)Clin J Oncol Nurs · 2004
• Anastrozole Regulates Fatty Acid Synthase in Breast CancerMol Cancer Ther · 2022
• Anastrozole-related dermatitis with mainly unilateral distributionAustralas J Dermatol · 2022
• Anastrozole: a selective aromatase inhibitor for the treatment of breast cancerAm J Health Syst Pharm · 1998